Stefan Schreiber
Overview
Explore the profile of Stefan Schreiber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
848
Citations
59458
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schlicht K, Pape L, Rohmann N, Knappe C, Epe J, Geisler C, et al.
Gut Microbes
. 2025 Mar;
17(1):2474143.
PMID: 40045464
The interplay between bile acids (BAs) and metabolic diseases has gained importance in recent years, with a variety of studies investigating their relationship with diverging results. Therefore, in the present...
2.
Nash P, Kerschbaumer A, Konzett V, Aletaha D, Dorner T, Fleischmann R, et al.
Ann Rheum Dis
. 2025 Mar;
PMID: 40037995
In light of the introduction of new Janus kinase inhibitors (JAKi), new indications for JAKi and recent safety considerations that have arisen since the preceding consensus statement on JAKi therapy,...
3.
Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, et al.
RMD Open
. 2025 Mar;
11(1).
PMID: 40037922
Objectives: Long-term safety is fundamental for treatment decision-making. This integrated analysis of filgotinib clinical trials in rheumatoid arthritis (RA) and ulcerative colitis (UC) assessed adverse events of interest (AEI): major...
4.
Neumann C, Hartung T, Boje K, Bahmer T, Keil J, Lieb W, et al.
Sci Rep
. 2025 Feb;
15(1):6833.
PMID: 40000883
Long-term changes in health-related quality of life (HrQoL) after SARS-CoV-2 infection are common, but their causes and consequences are poorly understood. This prospective, population-based study examined associations between HrQoL and...
5.
Lewis J, Vadhariya A, Su S, Zhou X, Durand F, Kawata A, et al.
J Patient Rep Outcomes
. 2025 Feb;
9(1):19.
PMID: 39962027
Background: The Stool Frequency (SF) and Abdominal Pain (AP) items from the Crohn's Disease Activity Index are together referred to as the "Patient Reported Outcome" (PRO). The SF item measures...
6.
Krause-Kyora B, da Silva N, Kaplan E, Kolbe D, Wohlers I, Busch H, et al.
EBioMedicine
. 2025 Feb;
113:105591.
PMID: 39923740
Background: The hypomorphic variant rs11209026-A in the IL23R gene provides significant protection against immune-related diseases in Europeans, notably inflammatory bowel diseases (IBD). Today, the A-allele occurs with an average frequency...
7.
Panaccione R, Louis E, Colombel J, DHaens G, Peyrin-Biroulet L, Dubinsky M, et al.
J Crohns Colitis
. 2025 Jan;
19(1).
PMID: 39804294
Background And Aims: Treating ulcerative colitis (UC) in patients with prior advanced therapy (AT) exposure may be challenging. We report the efficacy and safety of risankizumab, a monoclonal interleukin 23p19...
8.
Feagan B, Colombel J, Panaccione R, Schreiber S, Ferrante M, Kamikozuru K, et al.
Gastro Hep Adv
. 2025 Jan;
4(1):100544.
PMID: 39802486
Background And Aims: We evaluated the association between endoscopic outcomes following risankizumab induction and subsequent rates of hospitalization and surgery through 52 weeks of risankizumab (both doses) maintenance therapy in...
9.
Sands B, Panaccione R, DHaens G, Schreiber S, Jairath V, DuVall A, et al.
Lancet Gastroenterol Hepatol
. 2025 Jan;
10(3):210-221.
PMID: 39793589
Background: Tamuzimod (VTX002) is a selective sphingosine 1-phosphate receptor 1 modulator in development for ulcerative colitis. We aimed to assess the safety and efficacy of tamuzimod in patients with moderately-to-severely...
10.
Heckl S, Schneider C, Kercher L, Behrens H, Gundlach J, Bernsmeier A, et al.
Sci Rep
. 2025 Jan;
15(1):1209.
PMID: 39775131
Hepatocellular cancer (HCC) therapy is in need for an ideal companion diagnostic. Preclinical experimental studies have identified the insulin receptor (IR) and its synergistic counterpart, the IGF1 receptor (IGF1R), as...